# Atara Biotherapeutics, Inc.: financial statements, quarterly

ATRA · Nasdaq · CIK 1604464 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/atra.md) · [Financials](/companies/atra/financials.md) · [Filings](/companies/atra/filings.md) · [Insiders](/companies/atra/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/atra/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2.1](/filings/0000950170-24-125389.md) | [4.3 d](/filings/0000950170-25-035507.md) | [27.4](/filings/0000950170-25-072040.md) | [28.6](/filings/0000950170-25-106550.md) | [40.2](/filings/0001193125-25-276219.md) | [32.8 d](/filings/0001193125-26-108361.md) | [98.1](/filings/0001193125-26-219482.md) | [17.6](/filings/0001193125-26-346885.md) | [3.5](/filings/0001193125-25-276219.md) | [1.6 d](/filings/0001193125-26-108361.md) | [0.5](/filings/0001193125-26-219482.md) | [0.6](/filings/0001193125-26-346885.md) |
| Research and development | $m | [56.9](/filings/0000950170-24-125389.md) | [49.6 d](/filings/0000950170-25-035507.md) | [45.5](/filings/0000950170-25-072040.md) | [33.3](/filings/0000950170-25-106550.md) | [43.9](/filings/0001193125-25-276219.md) | [28.7 d](/filings/0001193125-26-108361.md) | [27.4](/filings/0001193125-26-219482.md) | [7.3](/filings/0001193125-26-346885.md) | [2.9](/filings/0001193125-25-276219.md) | [(0.2) d](/filings/0001193125-26-108361.md) | [0.2](/filings/0001193125-26-219482.md) | [1.3](/filings/0001193125-26-346885.md) |
| Operating income | $m | [(69.6)](/filings/0000950170-24-125389.md) | [(60.0) d](/filings/0000950170-25-035507.md) | [(31.2)](/filings/0000950170-25-072040.md) | [(18.2)](/filings/0000950170-25-106550.md) | [(21.8)](/filings/0001193125-25-276219.md) | [(12.2) d](/filings/0001193125-26-108361.md) | [38.8](/filings/0001193125-26-219482.md) | [3.2](/filings/0001193125-26-346885.md) | [(3.6)](/filings/0001193125-25-276219.md) | [(2.6) d](/filings/0001193125-26-108361.md) | [(3.4)](/filings/0001193125-26-219482.md) | [(4.7)](/filings/0001193125-26-346885.md) |
| Interest expense | $m | [1.4](/filings/0000950170-24-125389.md) | [1.2 d](/filings/0000950170-25-035507.md) | [1.2](/filings/0000950170-25-072040.md) | [1.3](/filings/0000950170-25-106550.md) | [1.2](/filings/0001193125-25-276219.md) | [1.0 d](/filings/0001193125-26-108361.md) | [1.0](/filings/0001193125-26-219482.md) | [1.0](/filings/0001193125-26-346885.md) | [0.9](/filings/0001193125-25-276219.md) | [0.9 d](/filings/0001193125-26-108361.md) | [0.8](/filings/0001193125-26-219482.md) | [0.2](/filings/0001193125-26-346885.md) |
| Income tax | $m | [(0.0)](/filings/0000950170-24-125389.md) | [0.0 d](/filings/0000950170-25-035507.md) | [0.0](/filings/0000950170-25-072040.md) | [0.0](/filings/0000950170-25-106550.md) | [(0.0)](/filings/0001193125-25-276219.md) | [(0.0) d](/filings/0001193125-26-108361.md) | [0.0](/filings/0001193125-26-219482.md) | [0.0](/filings/0001193125-26-346885.md) | [0.0](/filings/0001193125-25-276219.md) | [0.0 d](/filings/0001193125-26-108361.md) | [0.0](/filings/0001193125-26-219482.md) | [0.0](/filings/0001193125-26-346885.md) |
| Net income | $m | [(69.8)](/filings/0000950170-24-125389.md) | [(60.5) d](/filings/0000950170-25-035507.md) | [(31.8)](/filings/0001193125-25-276219.md) | [(19.0)](/filings/0001193125-25-276219.md) | [(21.9)](/filings/0001193125-25-276219.md) | [(12.7) d](/filings/0001193125-26-108361.md) | [38.0](/filings/0001193125-26-346885.md) | [2.4](/filings/0001193125-26-346885.md) | [(4.3)](/filings/0001193125-25-276219.md) | [(3.4) d](/filings/0001193125-26-108361.md) | [(4.1)](/filings/0001193125-26-346885.md) | [(4.8)](/filings/0001193125-26-346885.md) |
| Diluted EPS | $ per share | [(16.40)](/filings/0000950170-24-125389.md) | not reported | [(5.65)](/filings/0000950170-25-072040.md) | [(3.10)](/filings/0000950170-25-106550.md) | [(2.93)](/filings/0001193125-25-276219.md) | not reported | [3.50](/filings/0001193125-26-219482.md) | [0.19](/filings/0001193125-26-346885.md) | [(0.32)](/filings/0001193125-25-276219.md) | not reported | [(0.29)](/filings/0001193125-26-219482.md) | [(0.32)](/filings/0001193125-26-346885.md) |
| Basic EPS | $ per share | [(16.40)](/filings/0000950170-24-125389.md) | not reported | [(5.65)](/filings/0000950170-25-072040.md) | [(3.10)](/filings/0000950170-25-106550.md) | [(2.93)](/filings/0001193125-25-276219.md) | not reported | [3.53](/filings/0001193125-26-219482.md) | [0.20](/filings/0001193125-26-346885.md) | [(0.32)](/filings/0001193125-25-276219.md) | not reported | [(0.29)](/filings/0001193125-26-219482.md) | [(0.32)](/filings/0001193125-26-346885.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [64.8](/filings/0000950170-23-057147.md) | [25.8](/filings/0000950170-25-035507.md) | [35.1](/filings/0000950170-24-056959.md) | [31.3](/filings/0000950170-24-095533.md) | [46.5](/filings/0000950170-24-125389.md) | [25.0](/filings/0001193125-26-108361.md) | [13.8](/filings/0000950170-25-072040.md) | [16.9](/filings/0000950170-25-106550.md) | [5.7](/filings/0001193125-25-276219.md) | [8.5](/filings/0001193125-26-346885.md) | [8.4](/filings/0001193125-26-219482.md) | [3.2](/filings/0001193125-26-346885.md) |
| Current assets | $m | [119](/filings/0000950170-23-057147.md) | [102](/filings/0000950170-25-035507.md) | [106](/filings/0000950170-24-056959.md) | [62.4](/filings/0000950170-24-095533.md) | [91.9](/filings/0000950170-24-125389.md) | [64.9](/filings/0001193125-26-108361.md) | [27.2](/filings/0000950170-25-072040.md) | [24.8](/filings/0000950170-25-106550.md) | [18.4](/filings/0001193125-25-276219.md) | [12.2](/filings/0001193125-26-346885.md) | [12.2](/filings/0001193125-26-219482.md) | [13.5](/filings/0001193125-26-346885.md) |
| Total assets | $m | [189](/filings/0000950170-23-057147.md) | [166](/filings/0000950170-25-035507.md) | [165](/filings/0000950170-24-056959.md) | [117](/filings/0000950170-24-095533.md) | [143](/filings/0000950170-24-125389.md) | [109](/filings/0001193125-26-108361.md) | [62.0](/filings/0000950170-25-072040.md) | [36.9](/filings/0000950170-25-106550.md) | [30.2](/filings/0001193125-25-276219.md) | [20.2](/filings/0001193125-26-346885.md) | [20.0](/filings/0001193125-26-219482.md) | [21.0](/filings/0001193125-26-346885.md) |
| Current liabilities | $m | [79.1](/filings/0000950170-23-057147.md) | [142](/filings/0000950170-25-035507.md) | [181](/filings/0000950170-24-056959.md) | [148](/filings/0000950170-24-095533.md) | [156](/filings/0000950170-24-125389.md) | [135](/filings/0001193125-26-108361.md) | [47.9](/filings/0000950170-25-072040.md) | [14.6](/filings/0000950170-25-106550.md) | [18.1](/filings/0001193125-25-276219.md) | [14.9](/filings/0001193125-26-346885.md) | [5.6](/filings/0001193125-26-219482.md) | [6.8](/filings/0001193125-26-346885.md) |
| Total liabilities | $m | [240](/filings/0000950170-23-057147.md) | [265](/filings/0000950170-25-035507.md) | [264](/filings/0000950170-24-056959.md) | [228](/filings/0000950170-24-095533.md) | [233](/filings/0000950170-24-125389.md) | [206](/filings/0001193125-26-108361.md) | [117](/filings/0000950170-25-072040.md) | [71.9](/filings/0000950170-25-106550.md) | [66.8](/filings/0001193125-25-276219.md) | [58.7](/filings/0001193125-26-346885.md) | [57.3](/filings/0001193125-26-219482.md) | [58.0](/filings/0001193125-26-346885.md) |
| Shareholders' equity | $m | [(50.8)](/filings/0000950170-24-125389.md) | [99.2](/filings/0001193125-26-108361.md) | [(98.3)](/filings/0001193125-25-276219.md) | [(111)](/filings/0001193125-25-276219.md) | [(90.5)](/filings/0001193125-25-276219.md) | [(97.3)](/filings/0001193125-26-346885.md) | [(55.1)](/filings/0001193125-26-346885.md) | [(35.0)](/filings/0001193125-26-346885.md) | [(36.6)](/filings/0001193125-25-276219.md) | [(38.5)](/filings/0001193125-26-346885.md) | [(37.3)](/filings/0001193125-26-346885.md) | [(37.0)](/filings/0001193125-26-346885.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(51.3) d](/filings/0000950170-24-125389.md) | [(50.4) d](/filings/0000950170-25-035507.md) | [(29.6)](/filings/0000950170-25-072040.md) | [(10.6) d](/filings/0000950170-25-106550.md) | [(4.0) d](/filings/0001193125-25-276219.md) | [(24.5) d](/filings/0001193125-26-108361.md) | [(28.1)](/filings/0001193125-26-219482.md) | [(7.3) d](/filings/0001193125-26-346885.md) | [(9.8) d](/filings/0001193125-25-276219.md) | [(5.7) d](/filings/0001193125-26-108361.md) | [(3.1)](/filings/0001193125-26-219482.md) | [(3.3) d](/filings/0001193125-26-346885.md) |
| Capital expenditure | $m | [0.3 d](/filings/0000950170-24-125389.md) | [0.0 d](/filings/0000950170-25-035507.md) | [0.1](/filings/0000950170-25-072040.md) | [0.0 d](/filings/0000950170-25-106550.md) | [0.0 d](/filings/0001193125-25-276219.md) | [0.1 d](/filings/0001193125-26-108361.md) | [0.0](/filings/0000950170-25-072040.md) | [0.0 d](/filings/0000950170-25-106550.md) | [0.0 d](/filings/0001193125-25-276219.md) | [0.0 d](/filings/0001193125-26-108361.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [102](/filings/0000950170-23-057147.md) | [104](/filings/0000950170-24-056959.md) | [4.2](/filings/0000950170-24-095533.md) | [4.3](/filings/0000950170-24-125389.md) | [5.6](/filings/0000950170-25-072040.md) | [6.1](/filings/0000950170-25-106550.md) | [7.5](/filings/0001193125-25-276219.md) | [10.9](/filings/0001193125-26-219482.md) | [12.3](/filings/0001193125-26-346885.md) | [13.6](/filings/0001193125-25-276219.md) | [14.1](/filings/0001193125-26-219482.md) | [15.0](/filings/0001193125-26-346885.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 10,037,710 at 2026-08-10, from the cover of the [10-Q filed 2026-08-12](/filings/0001193125-26-346885.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.